<DOC>
	<DOCNO>NCT02266771</DOCNO>
	<brief_summary>The objective study determine effectiveness V.A.C.Veraflo negative pressure wound therapy instillation , compare historical control V.A.C Therapy without instillation management wound .</brief_summary>
	<brief_title>Impact V.A.C . Veraflo Therapy Wounds Requiring Debridement Within Orthopedic Practice</brief_title>
	<detailed_description>The V.A.C.Ulta™ Negative Pressure Wound Therapy System 510 ( k ) -cleared , Class II device ( K100657 ) follow indication use : `` V.A.C.Ulta™ Negative Pressure Wound Therapy System integrate wound management system provide Negative Pressure Wound Therapy instillation option . Negative Pressure Wound Therapy absence instillation intend create environment promote wound heal secondary tertiary ( delayed primary ) intention prepare wound bed closure , reduce edema , promote granulation tissue formation perfusion , remove exudate infectious material . The instillation option indicate patient would benefit vacuum assist drainage control delivery topical wound treatment solution suspension wound bed . The V.A.C.Ulta™ Negative Pressure Wound Therapy System , without instillation , indicate patient chronic , acute , traumatic , sub-acute dehisced wound , partial-thickness burn , ulcer ( diabetic , pressure venous insufficiency ) , flaps graft '' . The V.A.C . Ulta™ Therapy Unit use V.A.C.® Dressings ( V.A.C.® GranuFoam™ , V.A.C . GranuFoam Silver® , V.A.C . WhiteFoam , ® V.A.C . VeraFlo™ Dressing Systems ) disposable . The V.A.C . VeraFlo™ Dressing System intend use V.A.C . VeraFlo™ Therapy provide V.A.C.Ulta™ Therapy Unit . The V.A.C . VeraFlo™ Dressing clear V.A.C Ulta™ Negative Pressure Wound Therapy System 510 ( k ) ( K100657 ) . It recommend use open wound , include wound shallow undermining tunnel area distal aspect visible . Prontosan® Wound Irrigation Solution clear , odorless , colorless solution consist polyhexamethylene biguanide ( PHMB ) , betaine , sodium hydroxide purify water . PHMB , also know Polyhexanide , polymer biguanide . PHMB cationic preservative inhibits growth microorganisms within product . Betaine zwitterionic ( , negatively positively charge ) surfactant . Prontosan® FDA 510 ( k ) clear device intend cleaning wound moisten lubricate absorbent wound dress ulcer , burn , post surgical wound , abrasion . The objective study determine effectiveness V.A.C.Veraflo negative pressure wound therapy Prontosan instillation , compare historical control V.A.C Therapy without instillation management wound . We measure difference length hospital stay , number day final surgical procedure , number trip additional debridement . Patients consider infection free clinical sign infection absent lab value become normal .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<criteria>Signed Informed Consent . Patients require surgical debridement wound expose hardware and/or bone , traumatic wound , dehisce wound , postsurgical wound , pressure ulcers/sores require debridement . Age : 18 year . Gender : Male Female . No use Investigational Agents/Devices study within 30 day prior enrollment . Subjects locally available next 6 month . Wounds involve prosthetic joint . Patients unable adhere schedule study visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Negative Pressure Wound Therapy , Wound VAC , Instillation</keyword>
</DOC>